WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002028808) TRIPTYCENE ANALOGS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/028808    International Application No.:    PCT/US2001/031664
Publication Date: 11.04.2002 International Filing Date: 09.10.2001
IPC:
C07C 43/23 (2006.01), C07C 49/665 (2006.01), C07C 49/753 (2006.01), C07C 50/22 (2006.01), C07C 50/36 (2006.01), C07C 69/00 (2006.01), C07C 225/32 (2006.01), C07C 229/14 (2006.01), C07C 229/26 (2006.01), C07C 323/58 (2006.01), C07D 473/00 (2006.01), C07D 473/34 (2006.01), C07H 15/12 (2006.01)
Applicants: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION [US/US]; 1500 Hayes Drive Manhattan, KS 66502-5014 (US)
Inventors: HUA, Duy, H.; (US).
PERCHELLET, Jean-Pierre; (US)
Agent: DOUGHTY, Susan, K.; Greenlee, Winner and Sullivan, P.C. 5370 Manhattan Circle Suite 201 Boulder, CO 80303 (US)
Priority Data:
60/238,856 06.10.2000 US
Title (EN) TRIPTYCENE ANALOGS
(FR) ANALOGUES DE TRIPTYCÈNE
Abstract: front page image
(EN)This invention provides analogs of triptycene which are useful as anticancer drugs, as well as for other uses. The potency of these compounds is in a similar magnitude as daunomycin, a currently used anticancer drug. Each compound of the invention produces one or more desired effects (blocking nucleoside transport, inhibiting nucleic acid or protein syntheses, decreasing the proliferation and viability of cancer cells, inducing DNA fragmentation or retaining their effectiveness against multidrug-resistant tumor cells).
(FR)Cette invention a trait à des analogues de tritycène s"avérant des plus utiles en tant que médicaments anticancéreux ou utilisés à d"autres fins. L"efficacité de ces composés est similaire de celle de la daunomycine, médicament anticancéreux habituellement employé. Chaque composé selon cette invention a un ou plusieurs effets souhaités, notamment le blocage du transport de nucléosides, l"inhibition de la synthèse d"acide nucléiques ou de protéines, le ralentissement de la prolifération et de la viabilité de cellules cancéreuses, le déclenchement de la fragmentation de l"ADN ou le maintien de son efficacité à l"encontre de cellules tumorales résistant à une polythérapie.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)